Novel approaches to promote healing of bone loss in inflammatory arthritis
促进炎症性关节炎骨质流失愈合的新方法
基本信息
- 批准号:10365023
- 负责人:
- 金额:$ 53.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-14 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:Adaptor Signaling ProteinAllelesAnabolic AgentsAntibodiesArthritisBindingBinding SitesBiochemicalBiologicalBone MarrowBone necrosisCell Culture TechniquesCell LineageCellsClinicalDataDevelopmentDiseaseFractureGenetic TranscriptionGrantHistologicHistologyHumanIn VitroInflammationInflammatoryInflammatory ArthritisInterleukin-17JawJointsKnee jointKnock-inLeadLinkMAP Kinase GeneMass Spectrum AnalysisMediatingMessenger RNAModelingMolecularMusMutationNF-kappa BNew AgentsOsteoblastsOsteoclastsOsteogenesisOsteopeniaOsteoporosisOsteoporosis preventionPathway interactionsPatientsPharmaceutical PreparationsPhasePhosphorylationProductionProteinsRNA InterferenceRecombinant adeno-associated virus (rAAV)ResolutionRheumatoid ArthritisSerumSiteStromal CellsSynovitisTNF geneTestingTherapeutic AgentsTherapeutic UsesTranscriptUp-RegulationValidationWNT Signaling PathwayWorkadeno-associated viral vectorankle jointantagonistbasebeta cateninbonebone erosionbone healingbone lossbone massbone repaircytokineexperimental studygene therapyhealingin vitro Modelin vivoinhibitorinnovationjoint inflammationlong bonemicroCTmouse modelmutantnovelnovel strategiesnovel therapeuticsosteoblast differentiationoverexpressionpreventpromoterresponseside effectspine bone structuretherapeutic targettranscriptometranscriptomics
项目摘要
Rheumatoid arthritis (RA) leads to bone loss by activating osteoclasts (OCs) to resorb bone while suppressing
the ability of osteoblasts (OBs) to build bone. Importantly, patients with RA develop systemic
osteopenia/osteoporosis that is not well controlled by current therapeutic agents. Therefore, it is critical to
develop new agents that are anabolic for bone in the setting of inflammatory arthritis. Previously, we identified
the adaptor protein Schnurri-3 (SHN3) as a potent inhibitor of bone formation. Mice lacking SHN3 develop a
progressive increase in bone mass, as SHN3 deletion enhances OB function. Intriguingly, RA patients express
SHN3 in cells within inflamed synovium and in serum, and SHN3 expression is induced in vitro in OBs and in
synoviocytes (FLS) isolated from RA patients in response to the RA-associated cytokines TNF and IL-17A.
Notably, our preliminary data show that SHN3-deficiency can protect from inflammation-induced bone loss in
vitro and in vivo. Therefore, inhibition of SHN3 is an attractive mechanism to promote bone formation to
treat the local and systemic bone loss that accompanies RA. Finally, we have developed a bone-specific
recombinant adeno-associated virus (rAAV) that targets SHN3 and could prevent or treat bone loss in RA.
Aim 1 will test whether SHN3-deficiency can limit the development of osteoporosis and bone erosion in a TNF-
induced RA model by augmenting OB function, and can promote healing of articular erosions in a serum transfer-
induced arthritis model. Additionally, we will test the hypothesis that SHN3-deficiency in OBs prevents the
suppression of osteogenesis by the RA-associated cytokines TNF and IL-17A, while its deficiency in FLS
suppresses production of inflammatory cytokines and WNT antagonists that lead to inhibition of OB
differentiation. Aim 2 will determine the molecular mechanisms by which SHN3 deficiency protects from
inflammation-induced suppression of osteogenesis to identify novel targets promoting bone formation. We will
examine how the RA-associated cytokines TNF and IL-17A induce upregulation of SHN3 transcripts via the NF-
kB pathway and stabilization of phosphorylated SHN3 via the ERK MAPK pathway, resulting in suppression of
the WNT/b-catenin pathway and OB differentiation. Aim 3 will determine whether bone-specific rAAV-mediated
silencing of SHN3 in vivo prevents inflammation-induced bone loss in RA. Systemic bone loss and articular
erosion will be quantified in mouse models of RA treated with the bone-specific rAAV carrying a SHN3 silencer.
Transcriptomic profiling will be performed in AAV-transduced OB-lineage cells isolated from RA mouse models
to identify potential molecular effectors in the SHN3 pathway that promote healing of inflammation-induced bone
loss. Successful completion of this work will provide proof-of-principle that SHN3-deficiency can
augment bone formation at sites of inflammation-induced bone loss in RA. Understanding how SHN3
inhibition protects from suppression of OB differentiation in this setting and identifying potential novel
regulators in the SHN3 pathway should provide important therapeutic targets for inflammatory arthritis.
类风湿性关节炎(RA)通过激活破骨细胞(OC)吸收骨,同时抑制
成骨细胞(OB)构建骨骼的能力。重要的是,RA患者会出现全身性疾病
目前的治疗剂不能很好地控制骨质减少/骨质疏松症。因此,关键是
在炎症性关节炎的情况下开发新的骨合成代谢剂。此前,我们发现
衔接蛋白Schnurri-3(SHN 3)作为骨形成的有效抑制剂。缺乏SHN 3的小鼠发育为
随着SHN 3缺失增强OB功能,骨量逐渐增加。有趣的是,RA患者表示
SHN 3在炎症滑膜和血清中的细胞中表达,并且SHN 3表达在体外OB和
从RA患者分离的滑膜细胞(FLS)对RA相关细胞因子TNF和IL-17 A的应答。
值得注意的是,我们的初步数据表明,SHN 3缺乏可以保护炎症诱导的骨丢失,
体外和体内。因此,抑制SHN 3是促进骨形成的有吸引力的机制,
治疗伴随RA的局部和全身骨质流失。最后,我们开发了一种骨特异性
重组腺相关病毒(rAAV)靶向SHN 3,可以预防或治疗RA的骨丢失。
目的1将测试SHN 3缺乏是否可以限制TNF-α诱导的骨质疏松症和骨侵蚀的发展。
通过增强OB功能诱导RA模型,并能促进血清转移中关节糜烂的愈合,
诱导性关节炎模型。此外,我们还将检验OBs中SHN 3缺陷会阻止
RA相关细胞因子TNF和IL-17 A抑制骨生成,而其在FLS中的缺陷
抑制导致OB抑制的炎性细胞因子和WNT拮抗剂的产生
分化目的2将确定SHN 3缺陷保护的分子机制,
炎症诱导的骨生成抑制,以鉴定促进骨形成的新靶点。我们将
研究RA相关细胞因子TNF和IL-17 A如何通过NF-κ B诱导SHN 3转录物的上调。
kB途径和通过ERK MAPK途径稳定磷酸化SHN 3,导致抑制
WNT/β-catenin通路与OB分化。目的3将确定骨特异性rAAV介导的
SHN 3在体内的沉默防止了RA中炎症诱导的骨丢失。全身性骨丢失和关节
将在用携带SHN 3沉默物的骨特异性rAAV处理的RA小鼠模型中定量侵蚀。
将在从RA小鼠模型分离的AAV转导的OB谱系细胞中进行转录组学分析。
鉴定SHN 3通路中促进炎症诱导骨愈合的潜在分子效应物
损失这项工作的成功完成将提供SHN 3缺陷可以
增加RA炎症诱导骨丢失部位的骨形成。了解SHN 3
在这种情况下,抑制可防止OB分化受到抑制,并鉴定潜在的新的
SHN 3通路中的调节剂应该为炎性关节炎提供重要的治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ellen M Gravallese其他文献
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study
嵌合抗原受体(CAR)T细胞疗法用于存在自身免疫性或炎症性疾病患者癌症治疗的安全性:一项回顾性对比队列研究
- DOI:
10.1016/s2665-9913(24)00402-8 - 发表时间:
2025-04-01 - 期刊:
- 影响因子:16.400
- 作者:
Kathleen M M Vanni;Kaitlin R McCarter;Xiaosong Wang;Caitlyn Duffy;Jamie P Dela Cruz;Holly Wobma;Sarah Nikiforow;Elena M Massarotti;Karen H Costenbader;Jessica S Little;Ellen M Gravallese;Gregory C McDermott;Caron A Jacobson;Jeffrey A Sparks - 通讯作者:
Jeffrey A Sparks
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
风湿病领域未满足的需求:2023年靶向治疗进展会议报告
- DOI:
10.1136/ard-2023-224916 - 发表时间:
2024-04-01 - 期刊:
- 影响因子:20.600
- 作者:
Kevin L Winthrop;Philip Mease;Andreas Kerschbaumer;Reinhard E Voll;Ferdinand C Breedveld;Josef S Smolen;Jacques-Eric Gottenberg;Xenofon Baraliakos;Hans P Kiener;Daniel Aletaha;John D Isaacs;Maya H Buch;Mary K Crow;Jonathan Kay;Leslie Crofford;Ronald F van Vollenhoven;Caroline Ospelt;Stefan Siebert;Margreet Kloppenburg;Iain B McInnes;Ellen M Gravallese - 通讯作者:
Ellen M Gravallese
Ellen M Gravallese的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ellen M Gravallese', 18)}}的其他基金
Novel approaches to promote healing of bone loss in inflammatory arthritis
促进炎症性关节炎骨质流失愈合的新方法
- 批准号:
10590694 - 财政年份:2022
- 资助金额:
$ 53.97万 - 项目类别:
Novel approaches to the treatment of bone loss in rheumatoid arthritis
治疗类风湿性关节炎骨质流失的新方法
- 批准号:
9572399 - 财政年份:2017
- 资助金额:
$ 53.97万 - 项目类别:
Novel approaches to the treatment of bone loss in rheumatoid arthritis
治疗类风湿性关节炎骨质流失的新方法
- 批准号:
9435618 - 财政年份:2017
- 资助金额:
$ 53.97万 - 项目类别:
The STING pathway and cytosolic nucleic acid sensors in bone homeostasis
骨稳态中的 STING 通路和胞质核酸传感器
- 批准号:
10190834 - 财政年份:2017
- 资助金额:
$ 53.97万 - 项目类别:
The STING pathway and cytosolic nucleic acid sensors in bone homeostasis
骨稳态中的 STING 通路和胞质核酸传感器
- 批准号:
9383723 - 财政年份:2017
- 资助金额:
$ 53.97万 - 项目类别:
The STING pathway and cytosolic nucleic acid sensors in bone homeostasis
骨稳态中的 STING 通路和胞质核酸传感器
- 批准号:
10115967 - 财政年份:2017
- 资助金额:
$ 53.97万 - 项目类别:
Regulatory role for cytosolic nucleic acid sensors in bone
细胞质核酸传感器在骨中的调节作用
- 批准号:
8808584 - 财政年份:2014
- 资助金额:
$ 53.97万 - 项目类别:
Regulatory role for cytosolic nucleic acid sensors in bone
细胞质核酸传感器在骨中的调节作用
- 批准号:
8919245 - 财政年份:2014
- 资助金额:
$ 53.97万 - 项目类别:
Inhibition of osteoblast function in bone erosion in rheumatoid arthritis
类风湿性关节炎骨侵蚀中成骨细胞功能的抑制
- 批准号:
8098159 - 财政年份:2009
- 资助金额:
$ 53.97万 - 项目类别:
Inhibition of osteoblast function in bone erosion in rheumatoid arthritis
类风湿性关节炎骨侵蚀中成骨细胞功能的抑制
- 批准号:
8493996 - 财政年份:2009
- 资助金额:
$ 53.97万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 53.97万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 53.97万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 53.97万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 53.97万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 53.97万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 53.97万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 53.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 53.97万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 53.97万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 53.97万 - 项目类别: